['diabetes', 'diabetes mellitus, type 1']
['faster-acting insulin aspart', 'insulin aspart', 'insulin degludec']

        Inclusion Criteria: - Male or female, 1 year above or equal to age below 18 years at the
        time of signing informed consent and below 18 years at the time of randomisation -
        Diagnosed with type 1 diabetes mellitus (based on clinical judgement and supported by
        laboratory analysis as per local guidelines) - Ongoing daily treatment with a basal-bolus
        insulin regimen using basal insulin analogue or Neutral Protamine Hagedorn (NPH) insulin
        for at least 90 days prior to the screening visit - HbA1c (glycosylated haemoglobin) below
        or equal 9.5% (80 mmol/mol) analysed by the central laboratory at the screening visit
        Exclusion Criteria: - More than one episode of diabetic ketoacidosis requiring
        hospitalisation within the last 90 days prior to the screening visit - Treatment with any
        medication for the indication of diabetes or obesity other than stated in the inclusion
        criteria in a period of 90 days before screening
      